Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

Brian Jonas, Mehrdad Abedi, Aaron Rosenberg, Naseem Esteghamat, Rasmus Hoeg, Lihong Qi, Eric Tam, Joseph Tuscano, George Yaghmour

Blood (2025) 146 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2025-3356

Published: 2025

Journal Articles

Hyperfractionated cyclophosphamide, bortezomib and dexamethasone for initial treatment of newly diagnosed multiple myeloma with renal dysfunction

Guneet Kaleka, Paul Kaesberg, Brian Jonas, Naseem Esteghamat, Joseph Tuscano, Aaron Rosenberg

Blood (2025) 146 (Supplement 1): 4057.

https://doi.org/10.1182/blood-2025-4057

Published: 2025

Journal Articles

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Shira Dinner, Brian Jonas, Antonio Curti, Stephane De Botton, Pau Montesinos, Karen W.L. Yee, Gail Roboz, William Blum, Gary Schiller, Jorge Cortes, Justin Watts, Andrew Wei, Aaron Sheppard, Hua Tian, Eunice Wang

Blood (2025) 146 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2025-3439

Published: 2025

Journal Articles

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Jonas, Sangeetha Venugopal, George Yaghmour, Manu Pandey, Anthony Selwyn Stein, Mikkael Sekeres, Namrata Chandhok, Rasmus Hoeg, Joseph Tuscano, Pamela Becker, Terrence Bradley, Eric Tam, Guido Marcucci, Paul Frankel, Jan Beumer, Steven Gore, Alexey Danilov, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2025-1651

Published: 2025

Journal Articles

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Gabriel Mannis, Nikolai Podoltsev, Deepa Jeyakumar, Justin Watts, Pankit Vachhani, Brian Jonas, Uma Borate, Eric Tam, Harry Erba, Yuling Shi, Donna Haney, William Rice, Rafael Bejar, Naval Daver

Blood (2025) 146 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2025-1645

Published: 2025

Journal Articles

Identification of TPR::FGFR1 fusion in an unusual case of concurrent acute B lymphoblastic leukemia and T-lymphoblastic lymphoma: Case report and review of literature

Heather Greene, Aneeqa Zafar, Elham Vali Betts, Brian Jonas, Farnoush Moen

Blood (2025) 146 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2025-6848

Published: 2025

Journal Articles

Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913

Deepa Jeyakumar, An To, Piyanuch Kongtim, Kiran Naqvi, Pamela Becker, Brian Jonas, Caspian Oliai, Gary Schiller, Matthew Wieduwilt, Lloyd Damon

Blood (2025) 146 (Supplement 1): 5241.

https://doi.org/10.1182/blood-2025-5241

Published: 2025

Journal Articles

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 6.

https://doi.org/10.1182/blood-2025-6

Published: 2025

Journal Articles

Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles

Justin Watts, Eunice Wang, Brian Jonas, William Donnellan, Jay Yang, Karen Seiter, Andrew Wei, Stephane De Botton, Amber Thomassen, Hua Tian, Jorge Cortes

Blood (2025) 146 (Supplement 1): 1659.

https://doi.org/10.1182/blood-2025-1659

Published: 2025

Journal Articles

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Jay Yang, Joseph Jurcic, Christian Recher, Pierre Fenaux, Andrew Wei, Antonio Curti, Justin Watts, Eunice Wang, Brian Jonas, Jorge Cortes, Aaron Sheppard, Sophia Wang, Stephane De Botton

Blood (2025) 146 (Supplement 1): 5213.

https://doi.org/10.1182/blood-2025-5213

Published: 2025

Journal Articles

Lack of efficacy of levocarnitine for the treatment of pegylated asparaginase-related hepatotoxicity during induction or salvage chemotherapy in adults with acute lymphoblastic leukemia: A comparative, retrospective, University of California hematologic malignancies consortium (UCHMC) study

Logan Deyo, Alyssa Guo, Scott Isom, Daria Gaut, Caspian Oliai, Bennett Caughey, Richard Fong, Lloyd Damon, Kevin Shieh, An To, Benjamin Lee, Deepa Jeyakumar, Brian Jonas, Ryan Cassaday, Matthew Wieduwilt

Blood (2025) 146 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2025-3328

Published: 2025

Journal Articles

Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Blood (2025) 146 (Supplement 1): 3320.

https://doi.org/10.1182/blood-2025-3320

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in California

Gwendolyn Ho, MD, Ted Wun, MD, Qian Li, MS, Ann M Brunson, MS, Aaron S Rosenberg, MD MS, Brian Jonas, MD PhD, Theresa Keegan, PhD MS

Blood (2016) 128 (22): 391.

https://doi.org/10.1182/blood.V128.22.391.391

Published: 2016

Journal Articles

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Courtney DiNardo, MD, Daniel Pollyea, MD MS, Keith Pratz, MD, Michael J. Thirman, MD, Anthony Letai, MD PhD, Mark Frattini, MD PhD, Brian Jonas, MDPhD, Joel Leverson, PhD, Ming Zhu, PhD, Martin Dunbar, DrPH, Nancy Falotico, Rachel Kirby, BA, Suresh Agarwal, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Rod A. Humerickhouse, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 327.

https://doi.org/10.1182/blood.V126.23.327.327

Published: 2015

Journal Articles

Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact

Aaron S Rosenberg, MD MS, Ann M Brunson, BS, Theresa HM Keegan, PhD MSc, Joseph Tuscano, MD, Ted Wun, MD, Brian Jonas, MDPhD

Blood (2015) 126 (23): 1305.

https://doi.org/10.1182/blood.V126.23.1305.1305

Published: 2015

Journal Articles

The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment

Aaron S Rosenberg, MD MS, Ann M Brunson, BS, Theresa HM Keegan, PhD MSc, Brian Jonas, MDPhD, Joseph Tuscano, MD, Ted Wun, MD

Blood (2015) 126 (23): 1991.

https://doi.org/10.1182/blood.V126.23.1991.1991

Published: 2015

Journal Articles

A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies

Jeffrey E Lancet, MD, Andrew H Wei, MBBS, PhD, Simon TS Durrant, Mark S. Hertzberg, MBBS, PhD, FRACP, FRCPA, Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Ian D Lewis, MB, BS, PhD, Brian Jonas, MD, PhD, Jorge E. Cortes, MD, Geoffrey Yarranton, PhD, Jackie M. Walling, MBChB, PhD

Blood (2013) 122 (21): 3838.

https://doi.org/10.1182/blood.V122.21.3838.3838

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

Hyperfractionated cyclophosphamide, bortezomib and dexamethasone for initial treatment of newly diagnosed multiple myeloma with renal dysfunction

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Identification of TPR::FGFR1 fusion in an unusual case of concurrent acute B lymphoblastic leukemia and T-lymphoblastic lymphoma: Case report and review of literature

Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Lack of efficacy of levocarnitine for the treatment of pegylated asparaginase-related hepatotoxicity during induction or salvage chemotherapy in adults with acute lymphoblastic leukemia: A comparative, retrospective, University of California hematologic malignancies consortium (UCHMC) study

Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in California

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact

The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment

A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only